Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H7N2O2S.Na |
| Molecular Weight | 194.187 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC1=CC=C(C=C1)S([NH-])(=O)=O
InChI
InChIKey=CGRKCGWEOIQFRD-UHFFFAOYSA-N
InChI=1S/C6H7N2O2S.Na/c7-5-1-3-6(4-2-5)11(8,9)10;/h1-4H,7H2,(H-,8,9,10);/q-1;+1
| Molecular Formula | C6H8N2O2S |
| Molecular Weight | 172.205 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
63.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5636244/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.37% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5636244/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
Other AEs: Local reaction... Other AEs: Local reaction (0.2%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Local reaction | 0.2% | 15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? | 2001 Apr |
|
| Molecular and crystal structures of N-arylglycopyranosylamines formed by reaction between sulfanilamide and D-ribose, D-arabinose and D-mannose. | 2001 Apr 12 |
|
| Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. | 2001 Apr 28 |
|
| 5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. | 2001 Feb |
|
| Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. | 2001 Feb 1 |
|
| Characterisation of carbonic anhydrase in Plasmodium falciparum. | 2001 May 15 |
|
| E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. | 2001 Nov |
|
| Epidemiological analysis of Salmonella enteritidis isolates in Singapore. | 2001 Oct |
|
| Salt effects in capillary zone electrophoresis. V. Adsorption and retention of electrically neutral analytes. | 2001 Sep 21 |
|
| [Clinico-immunologic effect of immunomodulin and bactim in duodenal ulcer under environmental pollution conditions]. | 2002 |
|
| Antimicrobial resistance and plasmid profiles of Campylobacter jejuni and Campylobacter coli from human and animal sources. | 2002 |
|
| Tandem vicarious nucleophilic substitution of hydrogen/intramolecular Diels-Alder reaction of 1,2,4-triazines into functionalized cycloalkenopyridines. | 2002 Apr |
|
| Sulphonamide residues in eggs following drug administration via the drinking water. | 2002 Apr |
|
| Pneumocystis pneumonia. | 2002 Dec |
|
| Improving broad specificity hapten recognition with protein engineering. | 2002 Jul 17 |
|
| Release characteristics of pectin microspheres prepared by an emulsification technique. | 2002 Jul-Aug |
|
| 'In vitro' study of chemotherapeutic activity of sulphimidazole on some sensitive and metronidazole-resistant Trichomonas vaginalis strains. | 2002 Nov |
|
| Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. | 2003 |
|
| [Treatment of patients with acute pneumonia]. | 2003 Apr-Jun |
|
| [Treatment of sulfanilamide production wastewater by resin adsorption technique]. | 2003 Nov |
|
| Drug-induced bilateral transient myopia with the sulphonamide sulphasalazine. | 2003 Nov |
|
| Investigation of structural and dynamic features of the radicals produced in gamma irradiated sulfanilamide: an ESR study. | 2003 Nov 28 |
|
| Validated HPLC method for the determination of ranitidine in plasma. | 2003 Oct |
|
| Carbonic anhydrase inhibitors: inhibition of human and murine mitochondrial isozymes V with anions. | 2003 Sep 1 |
|
| High-performance liquid chromatography/inductively coupled plasma mass spectrometry and tandem mass spectrometry for the detection of carbon-containing compounds. | 2004 |
|
| Integron analysis and genetic mapping of antimicrobial resistance genes in Salmonella enterica serotype Typhimurium. | 2004 |
|
| Simultaneous determination of cefatrizine and clavulanic acid in dog plasma by HPLC. | 2004 Apr 1 |
|
| Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. | 2004 Aug 20 |
|
| A new method for purification of carbonic anhydrase isozymes by affinity chromatography. | 2004 Feb |
|
| Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. | 2004 Feb 23 |
|
| Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. | 2004 Feb 26 |
|
| Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. | 2004 Jul 16 |
|
| Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy. | 2004 Jun |
|
| Emerging issues in infective endocarditis. | 2004 Jun |
|
| Contamination of honey by the herbicide asulam and its antibacterial active metabolite sulfanilamide. | 2004 Jun |
|
| Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. | 2004 Jun |
|
| [Preparation of monoclonal antibody against sulfadiazine and development of an ELISA kit]. | 2004 Mar |
|
| Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. | 2004 Mar |
|
| An experimental animal model of aseptic loosening of hip prostheses in sheep to study early biochemical changes at the interface membrane. | 2004 Mar 3 |
|
| Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. | 2004 May 4 |
|
| Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. | 2004 Nov 1 |
|
| Drinking-water nitrate, methemoglobinemia, and global burden of disease: a discussion. | 2004 Oct |
|
| Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. | 2004 Oct 4 |
|
| Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. | 2004 Sep |
Sample Use Guides
One applicatorful (about 6g) intravaginally once or twice daily. Improvements in symptoms should
occur within a few days, but treatment should be continued for a period of 30 days.
Route of Administration:
Vaginal
Antimicrobial activity of sulfanilamide was tested with different bacterial and yeast strains. MIC values were 8 ug/ml for Listeria innocua, Escherishia coli and Pseudomonas aeruginosa; 16 ug/ml for Staphylococcus aureu and Candida albicans; 100 ug/ml for Botrytis cinerea and Fusarium oxysporum culmorum.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:16 GMT 2025
by
admin
on
Mon Mar 31 17:46:16 GMT 2025
|
| Record UNII |
4ZB6W6B524
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4ZB6W6B524
Created by
admin on Mon Mar 31 17:46:16 GMT 2025 , Edited by admin on Mon Mar 31 17:46:16 GMT 2025
|
PRIMARY | |||
|
DTXSID00143688
Created by
admin on Mon Mar 31 17:46:16 GMT 2025 , Edited by admin on Mon Mar 31 17:46:16 GMT 2025
|
PRIMARY | |||
|
12226950
Created by
admin on Mon Mar 31 17:46:16 GMT 2025 , Edited by admin on Mon Mar 31 17:46:16 GMT 2025
|
PRIMARY | |||
|
10103-15-8
Created by
admin on Mon Mar 31 17:46:16 GMT 2025 , Edited by admin on Mon Mar 31 17:46:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |